Cancer Molecular Imaging

癌症分子成像

• 批准号: 7944543
• 负责人: Anna M Wu
• 金额: $ 5.35万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-02 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944543
• 关键词: Abnormal Cell; Address; Advanced Development; Animal Model; Animals; Area; Area Analyses; Attention; Biochemical Process; Biological; Biological Process; Cancer Biology; Cancer Center Support Grant; Cancer Detection; Cancer Patient; Cancer Survivor; Cell Communication; Cell Therapy; Cells; Chronic; Clinic; Clinical; Clinical Treatment; Clinical Trials; Collaborations; Complex; DRD2 gene; Detection; Development; Diagnosis; Discipline; Disease; Disease Progression; Dopamine; Effectiveness; Engineering; Evaluation; Event; Fostering; Funding; Gefitinib; Gene Expression; Genomics; Gifts; Glioblastoma; Goals; Grant; Health; Herpesvirus 1; Homeostasis; Human; Image; Imaging Device; Imaging technology; Immune; Immune response; Immunotherapy; Individual; Inflammation; Institution; Investigation; Jonsson Comprehensive Cancer Center of University of California Los Angeles; Kinetics; Label; Laboratories; Leadership; Life; Lilium; Malignant Neoplasms; Measurement; Measures; Microfluidics; Modeling; Molecular; Molecular Probes; Molecular Target; Monitor; National Cancer Institute; Organism; Patients; Peer Review; Physics; Play; Positron-Emission Tomography; Pre-Clinical Model; Prevention; Procedures; Process; Proteomics; Publications; Radiolabeled; Reporter Genes; Research Personnel; Resolution; Resource Sharing; Rodent Model; Role; Scientist; Screening procedure; Seeds; Signal Transduction; Syndrome; System; T-Lymphocyte; Techniques; Therapeutic; Tracer; Translating; Translations; Tumor Biology; Tumor Immunity; Viral; analytical method; analytical tool; base; body system; cancer cell; cancer imaging; cancer immunotherapy; cancer initiation; cancer therapy; cell transformation; chemobrain; chemotherapy; clinical application; cost; design; imaging probe; improved; in vivo; inhibitor/antagonist; innovation; insight; instrument; instrumentation; interest; malignant breast neoplasm; mathematical model; melanoma; member; molecular imaging; multimodality; non-invasive monitor; novel; oncology; preclinical study; prevent; programs; radiotracer; research clinical testing; response; restoration; technology development; therapeutic gene; therapeutic target; therapy development; tool; tumor initiation

The Cancer Molecular Imaging Program Area is composed of 18 members, spanning 7 Departments within UCLA. In the past competing cycle, investigators from this Program authored 265 publications, of which 232 (88%) were inter-programmatic and 89 (34%) intra-programmatic. 71 (27%) were placed in high-impact ournals. Nine members of this Program Area used 6 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled $4.4 million in total costs, including $3.8 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CMI Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CMI Program Area total $317,584. These funds supported Seed Grants, recruitment/retention & Program Area Leadership support. Four of the Program Area Members were the recipients of JCCC support. Molecular imaging is a powerful set of approaches to reveal functional changes in living subjects that has enabled compelling insights into human health and disease. The newly proposed JCCC Cancer Molecular Imaging Program Area brings together investigators with a common focus on employing molecular imaging tools to investigate cancer in living individuals, from laboratory rodent models to patients. The efforts of CMI investigators are organized around four main themes. 1) Development of instrumentation and analytical tools. Moving molecular imaging forward requires constant development and improvement in instrumentation to provide higher resolution, sensitivity, and quantitative measurement of biological molecules and processes in vivo. 2) Development of novel molecular imaging approaches. CMI Program Area members have been leaders in the field of molecular imaging, with significant contributions in novel tracers, imaging gene expression using reporter genes, developing animal models to exploit the advantages of non-invasive, repeated and quantitative imaging, and in development of multimodality imaging instrumentation and analytic procedures. These tools are employed in the study of cancer initiation and progression, metastatic spread, and response to treatment, in preclinical models. 3) Imaging immune responses and response to immunotherapy. An important focus of the CMI Program Area is to develop the tools to monitor immune responses and follow the effects of cancer immunotherapy in living individuals. 4) Translation of imaging technologies to clinical contexts for cancer patients. Ultimately, the goal of the CMI Program Area is to improve the understanding, detection, and treatment of cancer. CMI Program Area members pursue translational goals that include both determining the best use of currently available molecular tracers in the clinic (e.g., FDG-PET, FLT-PET) as well as translating new molecular tracers through clinical evaluation.

癌症分子影像项目领域由 18 名成员组成，涵盖 7 个部门 加州大学洛杉矶分校。在过去的竞争周期中，该计划的研究人员撰写了 265 篇出版物，其中 232 篇 (88%) 是项目间的，89 (34%) 是项目内的。 71 名 (27%) 被安置在高影响力 期刊。该计划领域的 9 名成员使用了当前资助的 8 项共享资源中的 6 项 由联合商会。在本资助年度，同行评审资助的总成本为 440 万美元， 其中包括来自国家癌症研究所的 380 万美元。与其他计划领域一样，JCCC 培养了 支持 CMI 调查人员的互动活动和许多共享资源的数量 计划区。在当前的拨款周期中，JCCC 的资金以 CCSG Developmental 的形式提供 向 CMI 计划领域提供的资金、机构支持和慈善捐赠总计 317,584 美元。这些资金 支持种子拨款、招聘/保留和计划领域领导力支持。计划区之四 会员是 JCCC 支持的接受者。 分子成像是揭示活体功能变化的一组强大方法， 使人们能够对人类健康和疾病产生令人信服的见解。新提出的 JCCC 癌症分子 成像计划领域汇集了共同关注分子成像应用的研究人员 研究活体癌症的工具，从实验室啮齿动物模型到患者。 CMI的努力 调查人员围绕四个主题进行组织。 1) 仪器仪表和分析技术的发展 工具。推动分子成像的发展需要仪器的不断发展和改进 为生物分子和过程提供更高的分辨率、灵敏度和定量测量 体内。 2）新型分子成像方法的发展。 CMI 计划领域成员已 分子成像领域的领导者，在新型示踪剂、成像基因方面做出了重大贡献 使用报告基因进行表达，开发动物模型以利用非侵入性的优势， 重复和定量成像，以及多模态成像仪器和分析的开发 程序。这些工具用于研究癌症的发生和进展、转移扩散和 临床前模型中对治疗的反应。 3) 成像免疫反应和反应 免疫疗法。 CMI 计划领域的一个重要重点是开发监测免疫的工具 反应并跟踪癌症免疫治疗对活体个体的影响。 4) 成像翻译 将技术应用于癌症患者的临床环境。最终，CMI 计划领域的目标是 提高对癌症的了解、检测和治疗。 CMI 计划领域成员追求 转化目标包括确定当前可用分子示踪剂的最佳用途 临床（例如 FDG-PET、FLT-PET）以及通过临床评估转化新的分子示踪剂。